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JoThe Lancet Commission on Hypertension identified that a
key action to address the worldwide burden of high blood
pressure (BP) was to improve the quality of BP
measurements by using BP devices that have been
validated for accuracy. Currently, there are over 3000
commercially available BP devices, but many do not have
published data on accuracy testing according to
established scientific standards. This problem is enabled
through weak or absent regulations that allow clearance
of devices for commercial use without formal validation. In
addition, new BP technologies have emerged (e.g. cuffless
sensors) for which there is no scientific consensusrnal of Hypertension 2020, 38:21–29
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Sharman et al.validation standards specifically for new BP technologies
and online lists of accurate devices that are accessible to
consumers and health professionals. Recommendations are
aligned with WHO policies on medical devices and
universal healthcare. Adherence to recommendations
would increase the global availability of accurate BP
devices and result in better diagnosis and treatment of
hypertension, thus decreasing the worldwide burden from
high BP.
Keywords: biomedical technology, diagnostic equipment,
international health, reference standard
Abbreviations: AAMI, advancement of medical
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International Organisation for StandardizationINTRODUCTIONH
igh blood pressure (BP) is the leading modifiable
risk factor for cardiovascular disease, contributing
to the greatest global burden of disease [1,2]. There
are major deficiencies with respect to optimal awareness,
diagnosis and treatment of high BP, and these problems
persist across low-income, middle-income and high-
income countries, altogether emphasizing the need for
widespread population-level improvement [3]. Reassur-
ingly, if the presence of high BP can be correctly identified
with appropriate use of accurate BP devices and BP mea-
surement protocols, the risk of future cardiovascular events
can be reduced significantly with BP-lowering medications
[4], dietary and lifestyle interventions [5].
The accurate measurement of BP and the diagnosis of
hypertension are crucial because misclassification can have
serious clinical consequences [6]. An overestimation of BP
based on inaccurate measurement could lead to the initia-
tion, and potential lifelong continuation, of unnecessary
medications with possible side effects as well as unwanted
social effects including anxiety, workplace absenteeism [7]
and increased costs from insurance and medications [8].
Conversely, if inaccurate measurement results in under-
estimating BP, an opportunity to prevent avoidable cardio-
vascular events may be missed. These are nontrivial
problems, in that relatively small systematic inaccuracies
can lead to misclassification of many millions of people at
the population level [9]. Thus, accurate BP measurement
has been cited as one of the most important tests in clinical
medicine [10]. The accuracy of BP measurement is a serious
and frequent problem of contemporary clinical practice that
should be considered as an issue of patient safety.
One of the key actions of The Lancet Commission on
Hypertension was to improve BP evaluation from better
quality of BP measurements through endorsed protocols
and validated (accurate) BP monitors [11]. Manufacturers
must adhere to strict regulatory processes to bring a BP
device legally to market. However, many loopholes have
been identified which lead to BP devices of poor or
unknown accuracy being widely available for clinic use,
including for self-monitoring at home [12–19]. The effects22 www.jhypertension.comof unknown BP errors can influence the clinical environ-
ment, epidemiology and research, and even contribute to
discrepancies among hypertension guidelines [20]. From
about 3000 cuff-based BP measuring devices on the mar-
ket today, less than 15% have published evidence on
accuracy performance [21]. These nonvalidated BP devi-
ces are used in clinical practice and are more likely to be
inaccurate [22–24]. Furthermore, a variety of new BP
measurement technologies using sensors and cuffless
techniques are also now emerging for sale, but there is
minimal guidance on appropriate standards for accurately
testing them.
The aim of this article is both to summarize the current
situation regarding the regulatory requirements and accu-
racy standards for BPmeasuring devices, and also to redress
the problems mentioned above by providing recommen-
dations and actions towards improving validation and
reporting standards for BP measuring devices. This article
is fully aligned with the WHO policies on medical devices
and can assist to catalyse the full implementation of the
related World Health Assembly resolutions [25,26]. Ulti-
mately, this work seeks to facilitate the global availability
of validated BP measuring devices, thereby increasing the
probability of better BP management and decreasing the
worldwide burden of high BP.
HOWA BLOOD PRESSURE DEVICE
BECOMES APPROVED FOR SALE
Many countries have legal processes in place, whereby a
manufacturer of a BP device must demonstrate compliance
with regulatory requirements before being given clearance
for sale of the device. It is beyond this review to detail the
specific regulatory processes among different countries, as
these differ across the world and involve substantial com-
plexity. However, the general overriding principles of
regulatory processes are to ensure that BP devices meet
acceptable standards of quality, safety, reliability and effec-
tiveness (e.g. suitability for intended purpose).
If a company decides to market a BP device, it must
submit an application that is reviewed by the regulatory
authority within the jurisdiction of sale [e.g. the US Food
and Drug Administration (FDA, USA); Therapeutic Products
Directorate (Canada); or Therapeutic Goods Administration
(Australia), to name a few]. If the information provided by
the manufacturer meets the local regulatory requirements, a
licence (or clearance) is issued for sale of the device within
that country. In general, there are increasing levels of
regulatory requirements and assessments as the level of
potential risk from the device to the consumer rises. Thus,
as BP devices are classified as low-to-moderate risk, the
regulatory requirements are lower than those for high-risk
medical devices.
Although not required by law, a common way for the
manufacturer of a medical device to demonstrate compli-
ance with regulatory requirements is to show that the
device conforms with published standards relevant to that
device. Standards are documents designed to set out the
specifications, procedures and guidelines to ensure the
quality, safety and effectiveness of devices. The Interna-
tional Organisation for Standardization (ISO) developsVolume 38  Number 1  January 2020
Blood pressure device accuracy standardsstandards for use globally, but separate national or regional
standards may also exist.
STANDARDS FOR ASSESSINGTHE
ACCURACYOF BLOOD PRESSURE
MEASURING DEVICES
Efforts to validate BP devices formally started in the 1980s
[27]. In 1987, the US Association for the advancement of
medical instrumentation (AAMI) developed a clinical vali-
dation protocol for BP devices [28,29], which was followed
by a similar protocol from the British Hypertension Society
[30,31]. In 1999, the German Hypertension League devel-
oped another protocol [32] and in 2002 the European
Society of Hypertension (ESH) Working Group on BP
Monitoring developed their International Protocol, which
they revised in 2010 [33,34]. These protocols have been
revised by adopting more stringent criteria [29,31,34]. In
2004, the European Committee for Standardization (CEN)
published another standard [35], and in 2009 the ISO also
developed a standard [36] largely based on the AAMI and
CEN standards. This was adopted by AAMI [37]. In 2013, a
revised version of the AAMI/ISO Standard was
published [38].
While the abovementioned validation protocols and
standards have similarities in concept and core procedures,
they also have several methodological differences regard-
ing important issues such as the sample size required,
selection criteria for the participants, the validation proce-
dure, the efficacy measure and the criteria to pass [39]. This
variation has confused researchers, physicians, consumers
and manufacturers as to which protocol should be pre-
ferred and why. Furthermore, even when allegedly follow-
ing recommended protocols, investigators can make
incorrect claims about validation [40]. After three decades
of persistent efforts by several prestigious organizations for
optimizing the validation process there is no doubt that
science, the public, the regulatory bodies and industry
would be best served if a single standard for validation
of BP monitors is agreed and universally accepted.
In 2017, an international initiative to establish a univer-
sally acceptable standard for evaluating the accuracy of BP
measuring devices was put in place by the AAMI, ESH and
ISO committees [41]. This Standard (ISO 81060-2:2018) [42]
consolidates previous evidence and will progressively
replace all previous protocols used around the world. In
order for this initiative to achieve global impact for increas-
ing the availability of BP devices validated for clinical
accuracy, it would be necessary to make it mandatory to
use the universally accepted ISO Standard for assessing the
accuracy of BP measuring devices before they are put on
the market for use in the medical, community and
home settings.REGULATORY PATHWAY PROBLEMS
ANDOUTCOMES FOR BLOOD PRESSURE
DEVICES
There are significant problems in the transmission of scien-
tific data on BP device accuracy to the actual users of suchJournal of Hypertensiondevices [15,16,41,43–45]. Many important articles on the
deficiencies of BP measurement have been published over
many decades [10,46], but the information is rarely dissemi-
nated beyond the researchers and health professionals who
are already familiar with the problems. Manufacturers may
be aware of the limitations with respect to BP device
accuracy, but while the consumer market remains unaf-
fected, there is little impetus to modify practice.
A fundamental regulatory problem is that authorities
focus mainly on the physical safety features of BP devices
rather than accuracy and performance characteristics
[15,43]. Indeed, manufacturers are not required to test
accuracy according to specific unified standards, nor to
share results of the accuracy testing publicly. Regulations
can also be difficult to enforce due to ambiguities and high
levels of complexity [15]. In addition, recommendations
from consumer organizations are often based on cost,
usability and cosmetics rather than accuracy. Most insidi-
ously, unethical manufacturers are selling cheap home BP
devices online and making false claims with respect to
validation [47]. This implies that consumers may be more
likely to purchase lower priced, nonvalidated devices, but
this needs to be confirmed. Many other problems, summa-
rized in Table 1, have resulted in a marketplace replete with
BP devices of unknown or questionable accuracy [21–24].
EMERGING NEW BLOOD PRESSURE
DEVICEMETHODS ANDTECHNOLOGIES
Clinical guidelines for the diagnosis and management of
hypertension have been developed based on evidence from
auscultation or oscillometric arm cuff BP devices, which
remain the recommended standard for clinical practice.
These methods rely on analysis of haemodynamic signals
in the brachial artery, which were originally believed to be a
good estimate of the central aortic pressure load [48] as the
most clinically relevant BP [49–53]. In reality, cuff BP devices
vary greatly as to whether the measurements represent
central aortic or even brachial BP, and there may be large
individual variation in the SBP at the central aorta compared
with the brachial artery (e.g. difference >30mmHg) [54].
There are a variety of devices available that purport to
measure central aortic BP, as distinct from standard cuff
BP [55]. However, beyond recommendations of professional
societies [56], there are no regulatory standards to assess
performance of these devices.
There is also a burgeoning of new BP measurement
technologies that seek to measure BP in entirely different
ways than cuff BP. These include different types of cuffless
sensors at various arterial sites (e.g. chest, face, upper arm,
wrist, finger) with continuous or ‘snapshot’ monitoring of BP
using a variety of direct or indirect recording and signal
processing methods (e.g. reflectance pulse oximetry, radio
frequency sensors, microstructure strain gauge fibres, opto-
electronic, applanation tonometry, pulse transit time, smart-
phone applications) over durations that may extend to
weeks or months, and may incorporate software programs
with clinical decision-support functionality [57–66]. Some of
these methods are not user-friendly and many still rely on
calibration to a conventional cuff-based BP measurement,
which are limiting features. Nonetheless, this is an evolvingwww.jhypertension.com 23
TABLE 1. Summary of regulatory and validation study problems, results and consequences related to accuracy of blood pressure devices
Problem Result Overall consequences
Not mandatory for manufacturers to use a
specific standard to assess BP measuring
device accuracy
Variable methods used to assess and report on the
accuracy of BP measuring devices
Not mandatory for validation testing to be
performed by independent parties
Internal company testing performed with questionable
expertise and conflict of interest
Several published validation studies deviate
from established protocols
Questionable results and unjustified conclusions of studies
evaluating BP monitors
Several BP devices have passed regulatory
requirements for sale but failed
independent validation of measurement
accuracy
Erroneous messaging with respect to the accuracy of
individual BP devices
BP devices may fail to produce accurate
readings in people with large or small arms
but still used in such cases
Individuals with too small or too large arms may have
inaccurate BP evaluation
The assumption that a BP device ‘cleared’ by
regulatory authorities and commercially
available is accurate
Confusion as to which BP device available on the market
has acceptable accuracy
1. Inaccurate BP devices are widely available for
sale and use by clinicians and the general
public who are unaware of the problem
2. Incorrect diagnosis and treatment decisions are
made
3. Opportunity is lost to perform best-practice
clinical care and increase the efficacy of
cardiovascular disease prevention
Regulatory requirements focus on safety
rather than accuracy (performance)
BP devices perform well with regard to safety but may not
be accurate
Results of BP devices that fail validation
studies may not be published
Lack of widespread communication and transparency on
the results of validation studies
Exact BP device used in the validation study is
unclear
Confusion as to whether the BP device has undergone
validation testing
Unethical companies are selling cheap home
BP devices online with false validation
credentials
Consumers may favour purchase of cheap products, and
this could have particular impact among people in lower
income countries
Consumer organizations do not give due
attention to BP device accuracy
Inappropriate advice on best BP devices to use is
promulgated to the general public
BP, blood pressure.
Sharman et al.field with major opportunities to improve hypertension
evaluation and control, and also to advance systems of
healthcare delivery by merging with electronic medical
records. However, these diverse technologies also pose
new regulatory challenges in providing suitable oversight
regarding clinical performance, accuracy, safety and utility
[67].
RECOMMENDATIONS ANDACTIONSTO
ADDRESS IDENTIFIED PROBLEMS
Recommendation 1: Convergence toward the global regu-
latory requirement for mandatory independent validation
of BP devices according to the universally accepted ISO
Standard (ISO 81060-2:2018) with publication preferably
in a peer reviewed journal
According to the WHO, high-quality health technolo-
gies, such as validated BP devices, are indispensable for
effective universal healthcare delivery [25]. Indeed, the
WHO Global Model Regulatory Framework for Medical
Devices presents a stepwise approach to implementing
and enforcing regulatory controls for medical devices
[68]. Regulatory convergence is when the regulatory
requirements across different regions become aligned
due to the adoption of internationally recognized technical
documents or regulatory mechanisms that align with
achieving a common public health goal [69]. The ISO
Standard fulfils the urgent need for a single, universally
accepted protocol for BP device validation. The standard
has already been adopted by the United States, as well as24 www.jhypertension.commany other countries and, if made a global mandatory
regulatory requirement, will redress the majority of prob-
lems relating to BP device accuracy associated with current
frameworks. For this to occur there are numerous actions
that need to be undertaken across a wide spectrum of key
stakeholders that include: government organizations (e.g.
FDA or other regulatory agencies); nongovernment orga-
nizations (e.g. hypertension societies); researchers, health
professionals; journals that publish material related to BP;
manufacturers of BP devices and the consumers who
purchase BP devices. Nongovernment organizations have
many important roles to play. Indeed, endorsement of a
standardized validation protocol by a hypertension society
has been shown to influence manufacturers to pursue
independent validation of BP devices [39]. A summary of
required actions is detailed in Table 2.
Recommendation 2: Development of specific standards
for the validation of new BP measuring technologies that
cannot be tested using the ISO Standard (ISO 81060-
2:2018)
The worldwide inundation of new technology that
claims to measure BP brings challenges to regulatory
authorities that are also encouraging ways to find innova-
tive solutions [67]. Rather than repeating past regulatory
problems experienced with standard cuff BP devices, there
is an opportunity for developing international standards
that are specific to new BP technologies, and that appro-
priately evaluate accuracy and clinical validity. Table 2 sets
out the actions required to achieve this recommendation.
As with Recommendation 1, both government andVolume 38  Number 1  January 2020
TABLE 2. Recommendations and required actions by key stakeholders for the global improvement of blood pressure device accuracy
standards
Recommendations Key stakeholders to effect
actions
Actions
Convergence towards the global
regulatory requirement for
mandatory independent
validation of BP devices
according to the universally
accepted ISO Standard (ISO
81060-2:2018) with
publication preferably in a
peer reviewed journal
Government regulatory
organizations (e.g. US Food
and Drug Administration,
European Database on
Medical Devices, Australian
Therapeutic Goods
Administration)
Legislate for mandatory independent validation of BP devices according to the
ISO Standard before approval for sale
Stipulate that validation studies of BP devices are registered in an accepted
repository before approval for sale
Regulate enforcement of the ISO Standard
Monitor compliance with the ISO Standard
Support efforts of the WHO to implement WHA resolutions to ensure effective
use and strengthened regulatory systems for BP devicesa
Nongovernment organizations
(e.g. hypertension societies,
cardiovascular advocacy
groups)
Develop repositories for the registration of BP device validation studies
conducted around the world (similar concept to ClinicalTrials.gov)
Certify research facilities for performing BP device validation studies
Advocate and lobby to legislate for use of the ISO Standard
Endorse the use of BP devices that have passed validation according to the ISO
Standard
Educate members on the importance of using BP devices that have passed the
ISO Standard
Educate patients on the importance of BP device accuracy and access to
validated devices
Researchers Register BP device validation studies in an accepted repository
Transfer knowledge on BP device accuracy for the benefit of the wider
scientific, clinical and general community
Health professionals Only use validated BP devices in clinical practice
Ensure ongoing accuracy of BP devices used in clinical practice by undertaking
maintenance checks according to the manufacturer’s instructions
Educate patients to only use validated BP devices for self-home monitoring
Peer reviewed journals Only accept articles in which BP has been measured using devices that have
passed validation according to the ISO Standard
Manufacturers Evaluate the accuracy of BP devices using the ISO Standard through
independent researchers
Publish results of validation testing on company websites
Use a specific common identifier for each BP device that may be sold by
distributors under different names
Provide instructions to purchasers on the process for regular maintenance of
the specific device purchased
Consumers Only purchase BP devices that have passed validation
Ensure ongoing accuracy of BP device by undertaking regular maintenance
according to the manufacturer’s instructions
Only purchase BP devices when accuracy can be confirmed through accredited
online listsb
Development of specific
standards for the validation of
new BP measuring
technologies that cannot be
tested using the ISO Standard
(ISO 81060-2:2019)
Nongovernment organizations Develop international standards specifically for new BP measuring technologies
that cannot be tested using the current ISO Standards
Endorse the use of international standards for new BP measuring technologies
Government organizations Legislate for mandatory independent validation of new BP devices according to
the ISO Standard (developed by nongovernment organizations) before
approval for sale
Regulate enforcement of the international standards
Monitor compliance with the international standards
Researchers and biomedical
engineers
Participate in the development of international standards for new BP
measuring technologies
Develop new technologies to accurately measure BP
Conduct research to determine the ability of new BP technologies to enhance
clinical care
Health professionals Avoid using new BP measuring technologies until proven to enhance clinical
care
Accredited online lists of BP
devices detailing the published
results of the validation
studiesb
Government and
nongovernment organizations
Endorse and promote accredited online lists of BP devices
Develop and maintain one universally accepted accredited list of BP devices
Promote access to the accredited online lists of BP devices through the WHO
Essential Medicines and Health Products Programc
Facilitate acquisition of validated BP monitors (from accredited lists) to increase
quality and affordability through initiatives such as the PAHO Strategic Fundd
Researchers Participate in expert advisory groups to oversee the scientific credibility of
accredited online lists of BP devices
BP, blood pressure; ISO, International Organization for Standardization.
aWHA, World Health Assembly resolutions WHA60.29 and WHA67.20 https://www.who.int/healthsystems/WHA60_29.pdf and http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R20-
en.pdf.
bCurrent online lists of BP devices and validation information can be found at https://bihsoc.org/bp-monitors/, https://hypertension.ca/hypertension-and-you/managing-hypertension/
measuring-blood-pressure/devices/ https://medaval.ie/device-category/blood-pressure-monitors/ and https://stridebp.org/.
cWHO Essential Medicines and Health Products Program https://www.who.int/medicines/about/en/.
dPAHO, Pan American Health Organisation, Strategic Fund https://www.paho.org/hq/index.php?option=com_content&view=article&id=12167:faqs-strategic-
fund&Itemid=1694&lang=en#1.
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Sharman et al.nongovernment organizations will need to undertake
actions to develop the specific standards and legislate
for their mandatory use before approval for sale, but
also endorse, regulate and monitor compliance with the
new standards. Health professionals should avoid using
new BP technologies to inform clinical management until
the method in question can be proven to enhance
clinical care.
Recommendation 3: Accredited online lists of BP devices
detailing the published results of the validation studies
There is an urgent need to establish means of informing
the scientific and general community as to which BP
devices have been tested and found to have acceptable
accuracy. This can be achieved through online lists of BP
devices that detail the results of validation studies carried
out according to international standards [43]. The lists
should be developed and maintained by organizations with
sufficient expertise to ensure scientific rigor and remain
independent from BP device manufacturers. Such lists have
been developed by national scientific societies in the
United Kingdom [70] and Canada [71]. The American Medi-
cal Association and the American Heart Association [72], as
well as an international group of BP measurement experts
(STRIDE-BP organization) have also developed similar
resources for general use, which are important nonprofit
initiatives. As we move towards a single, universally-
accepted ISO Standard, so too we should work towards
developing one universally accepted accredited list of BP
devices to consolidate information for best effect. Table 2
summarizes the actions and key stakeholders to achieve
this recommendation.
IMPLEMENTATIONACTIONS BY THE
LANCETCOMMISSIONON
HYPERTENSIONGROUP
A co-ordinated program of activities to implement the
recommendations and actions set out in Table 2 is being
led by an executive team from the Lancet Commission on
Hypertension Group. This team will be guided by an
advisory team of invited members with relevant expertise
across diverse skills (e.g. scientific, technical, advocacy,
implementation science) and representing organizational
sectors (e.g. government and nongovernment organiza-
tions, professional societies) in different world regions.
Lobbying key decision-makers at national Department of
Health level is recognized as critical for successful knowl-
edge transfer. The executive team is also keen to leverage
opportunity for implementation through existing interna-
tional programmes and resources, such as the WHO Pro-
gramme on Cardiovascular Disease, and among individual
countries through local champions and relevant organiza-
tions (e.g. Heart and Stroke Foundations). The outcomes of
these activities will be evaluated and published. Interested
partners can contact the corresponding author of
this article.
CONCLUSION
Measurement of BP is a fundamental medical test per-
formed daily on many millions of people worldwide,26 www.jhypertension.comand health professionals together with consumers should
have confidence in the accuracy of the BP devices that they
use for screening, diagnosis and management of hyperten-
sion. On the contrary, due to a host of well known prob-
lems, the global marketplace has been inundated with BP
devices that are either known to be inaccurate or are of
unknown accuracy. This can have serious implications for
being able to achieve best-practice care of people related to
BP control. The problem also threatens to be compounded
by widespread introduction of new technology purporting
to measure BP. Fortunately, most identified problems could
be resolved by the mandatory requirement for independent
validation of BP devices according to the recently devel-
oped ISO Standard. Other key needs are the development
of specific standards for the validation of new BP technol-
ogies and accredited online lists of BP devices that are
accessible to health professionals and consumers. An exec-
utive team of the Lancet Commission on Hypertension
Group is currently working towards implementation of
the recommendations provided in this position statement.
Adherence to these recommendations would align with
WHO policy to result in more accurate diagnosis and
treatment of hypertension and a decrease in the worldwide
burden from high BP.
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